Cyclo Therapeutics Inc.
| NASDAQ: CYTH | Healthcare / Biotechnology / USA |
| 1.31 | -0.0600 | -4.38% | Vol 61.71K | 1Y Perf -18.93% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 1.29 | ASK | 1.57 | ||
| Open | 1.35 | Previous Close | 1.37 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 5.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 281.68 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★+ 43.61 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★+ 53.96 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 33.68 | Earnings Rating | — | |
| Market Cap | 29.78M | Earnings Date | 10th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.23 | |
| Beta | -0.03 |
Today's Price Range 1.301.51 | 52W Range 0.67002.57 | 5 Year PE Ratio Range -5.00-2.70 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -9.03% | ||
| 1 Month | 0.00% | ||
| 3 Months | -17.87% | ||
| 6 Months | -12.67% | ||
| 1 Year | -18.93% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -139.03 | |||
ROE last 12 Months | -200.35 | |||
ROA (5Y Avg) | -36.12 | |||
ROA last 12 Months | -135.45 | |||
ROC (5Y Avg) | -323.30 | |||
ROC last 12 Months | -198.39 | |||
Return on invested Capital Q | -55.27 | |||
Return on invested Capital Y | -23.62 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.20 | ||||
| 3.12 | ||||
| 14.41 | ||||
| 63.20 | ||||
| -1.40 | ||||
| -1.84 | ||||
| 3.12 | ||||
| 0.60 | ||||
| 13.22M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.60 | ||||
| 2.90 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 89.20 | ||||
| -755.90 | ||||
| -754.80 | ||||
| -589.10 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.19M | ||||
| 0.13 | ||||
| 12.94 | ||||
| -0.07 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.33 | - |
| Q01 2023 | - | -0.46 | - |
| Q03 2022 | - | -0.50 | - |
| Q02 2022 | - | -0.41 | - |
| Q01 2022 | - | -0.33 | - |
| Q03 2021 | - | -0.60 | - |
| Q02 2021 | - | -0.56 | - |
| Q01 2021 | - | -0.76 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 61.71K |
| Shares Outstanding | 22.73K |
| Shares Float | 11.71M |
| Trades Count | 278 |
| Dollar Volume | 83.69K |
| Avg. Volume | 55.20K |
| Avg. Weekly Volume | 27.33K |
| Avg. Monthly Volume | 84.30K |
| Avg. Quarterly Volume | 53.97K |
Cyclo Therapeutics Inc. (NASDAQ: CYTH) stock closed at 1.31 per share at the end of the most recent trading day (a -4.38% change compared to the prior day closing price) with a volume of 61.71K shares and market capitalization of 29.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Cyclo Therapeutics Inc. CEO is N. Scott Fine.
The one-year performance of Cyclo Therapeutics Inc. stock is -18.93%, while year-to-date (YTD) performance is -7.75%. CYTH stock has a five-year performance of %. Its 52-week range is between 0.67 and 2.57, which gives CYTH stock a 52-week price range ratio of 33.68%
Cyclo Therapeutics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 14.41, a price to cashflow ratio of 63.20, a PEG ratio of -, a ROA of -135.45%, a ROC of -198.39% and a ROE of -200.35%. The company’s profit margin is -%, its EBITDA margin is -754.80%, and its revenue ttm is $1.19 Million , which makes it $0.13 revenue per share.
Of the last four earnings reports from Cyclo Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclo Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cyclo Therapeutics Inc. is Strong Buy (1), with a target price of $5, which is +281.68% compared to the current price. The earnings rating for Cyclo Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cyclo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cyclo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 57.90, ATR14 : 0.16, CCI20 : -14.37, Chaikin Money Flow : -0.02, MACD : 0.05, Money Flow Index : 33.53, ROC : -6.43, RSI : 49.99, STOCH (14,3) : 42.75, STOCH RSI : 0.00, UO : 35.47, Williams %R : -57.25), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cyclo Therapeutics Inc. in the last 12-months were: F. Patrick Ostronic (Buy at a value of $7 485), Fine N. Scott (Buy at a value of $212 575), Francis Patrick Ostronic (Buy at a value of $7 785), Jeffrey Tate (Buy at a value of $42 516), Markus Sieger (Buy at a value of $7 485), N. Scott Fine (Buy at a value of $37 425)
Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
CEO: N. Scott Fine
Telephone: +1 386 418-8060
Address: 6714 NW 16th Street, Gainesville 32653, FL, US
Number of employees: 8
